Table 1.

A list of potential medications targeting key FRM-promoting molecules, currently tested in clinical trials. Available drugs are evaluated in ongoing clinical trials to determine their effects to inhibit NLRP3 inflammasome, IL1B, or IL18 in various conditions associated with an unresolved inflammatory status.

Medication	Role on IL1β or/and NLRP3 Inflammasome		Ongoing Clinical Trials
	Mode of Action	References	Clinical Trial Theme	Clinical Trial ID
Belnacasan	CASP-1 specific inhibitor, Prevents Il-1 β release	[102]	SARS-CoV-2	NCT05164120
Canakinumab	Inhibits IL-1β	[101]	Inflammation and Cardiovascular risk	NCT02272946
Colchicine	Decreases IL-1β, IL-18, and IL-6	[100]	Peripheral artery disease	NCT04774159
			Perioperative AF	NCT03310125
Dapansutrile	Blocks NLRP3 assembly, Prevents NLRP3-induced release of IL-1β and IL-18	[103]	Schnitzler’s syndrome	NCT03595371
				NCT04540120
Inzomelid	Prevents ASC release and NLRP3 activation	[104]	Cryopryrin-Associated Periodic syndromes	EudraCT2020-000489-40
			Parkinson’s disease	NCT04338997
Pirfenidone	Decreases NLRP3 and ASC expression Inhibits caspase-1 activation and Prevents IL-1β maturation	[105]	Pulmonary Fibrosis	NCT03109288
				NCT03109288
SGLT2 inhibitors	Prevents IL-1β release	[107]	Myocardial Infarction	NCT04899479
Somalix	Inhibits NLRP3 activation	[104]	Peripheral arterial disease	NCT04015076
Tranilast	Binds NACHT domain of NLRP3 to block NLRP3 oligonerization	[106]	Mucinoses	NCT03490708
			Cryopryrin-Associated Periodic syndromes	NCT03923140